101466-69-7

Basic information

• Product Name: methyl (+/-)-3-(4-chlorophenyl)-4-nitrobutanoate
• Synonyms: methyl (+/-)-3-(4-chlorophenyl)-4-nitrobutanoate
• CAS NO: 101466-69-7
• Molecular Weight: 257.674
• Mol File: 101466-69-7.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: methyl (+/-)-3-(4-chlorophenyl)-4-nitrobutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (+/-)-3-(4-chlorophenyl)-4-nitrobutanoate(101466-69-7)
• EPA Substance Registry System: methyl (+/-)-3-(4-chlorophenyl)-4-nitrobutanoate(101466-69-7)

Safety Data

• Hazardous Substances Data: 101466-69-7(Hazardous Substances Data)

Upstream product

• 75-52-5 nitromethane 
• 20754-21-6 methyl 3-(4-chlorophenyl)propenoate 
• 1615-02-7 3-(4-chlorophenyl)prop-2-enoic acid 
• 159112-23-9 3-(4-chlorophenyl)-4-nitrobutanoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 7560-44-3 methyl 4-chlorocinnamate 
• 104-88-1 4-chlorobenzaldehyde 
• 1075-77-0 (E)-4-chlorocinnamic aldehyde 
• 1489016-24-1 3-(4-chlorophenyl)-4-nitrobutanal 
• 67-56-1 methanol 

Downstream Products

• 159112-23-9 3-(4-chlorophenyl)-4-nitrobutanoic acid 
• 852051-18-4 methyl (R)-(+)-3-(4-chlorophenyl)-4-nitrobutanoate 
• 750649-51-5 (S)-(+)-3-(4-chloro-phenyl)-4-nitro-butyric acid 
• 69308-37-8 (R)-baclofen 
• 123632-31-5 (S)-(+)-4-(4-chlorophenyl)pyrrolidin-2-one 
• 123632-35-9 (R)-(-)-4-(4-chlorophenyl)pyrrolidin-2-one 
• 290366-79-9 (R)-(-)-3-(4-chloro-phenyl)-4-nitro-butyric acid 
• 63701-55-3 (R)-(-)-baclofen hydrochloride 
• 63701-56-4 (+)-Baclofen hydrochloride 
• 750649-48-0 (3S,3'S)-4,4-dimethyl-2-oxo-1-phenylpyrrolidin-3-yl 4-nitro-3-(4-chlorophenyl)butanoate 
• 750649-46-8 (3R,3'R)-4,4-dimethyl-2-oxo-1-phenylpyrrolidin-3-yl 4-nitro-3-(4-chlorophenyl)butanoate 
• 159112-11-5 N-<2-(4-chlorophenyl)-3-nitropropyl>-2,2,2-trifluoroacetamide 
• 149172-64-5 2-(4-chlorophenyl)-3-nitropropan-1-amine 
• 1134-47-0 4-amino-3-(4-chlorophenyl)butanoic acid 

Relevant articles and documents

Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design

A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, A12, that exhibited potent in vitro and in vivo antitumor efficacies; however, obvious safety issues limited its further development. Thus, systematic exploration of the structure-activity relationship of compound A12, involving the phenyl group, hinge-linkage, and piperidine moiety, led to the discovery of the superior 3,4,6-trisubstituted piperidine derivative E22. E22 showed increased potency in Akt1 and cancer cell inhibition, remarkably reduced human ether-a-go-go-related gene blockage, and significantly improved safety profiles. Compound E22 also exhibited good kinase selectivity, had a good pharmacokinetic profile, and displayed very potent in vivo antitumor efficacy, with over 90% tumor growth inhibition in the SKOV3 xenograft model. Further mechanistic studies were conducted to demonstrate that compound E22 could significantly inhibit the phosphorylation of proteins downstream of Akt kinase in cells and tumor tissue from the xenograft model.

TRICYCLIC DERIVATIVE

Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same.

Water-compatible iminium activation: Organocatalytic Michael reactions of carbon-centered nucleophiles with enals

(Chemical Equation Presented) A pool of water-compatible catalysts, namely the chiral prolinol-based catalysts 1, has been developed for highly enantioselective C-C bond-forming Michael reactions in water (see scheme). The synthesis of (S)-Rolipram, a type IV phosphodiesterase inhibitor, was also demonstrated.